Inhibikase Therapeutics Inc (IKT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.59 Million) by net assets ($72.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inhibikase Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IKT total liabilities for a breakdown of total debt and financial obligations.
Inhibikase Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prime Office A/S
CO:PRIMOF
|
0.007x |
|
Newcore Gold Ltd
V:NCAU
|
0.007x |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
0.013x |
|
Tonlin Department Store Co Ltd
TW:2910
|
0.020x |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
0.020x |
|
Tomer Energy Royalties (2012) Ltd
TA:DLRL
|
0.063x |
|
OMER S.P.A. O.N.
F:9WR
|
N/A |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
N/A |
Annual Cash Flow Conversion Efficiency for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Inhibikase Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $94.87 Million | $-19.15 Million | -0.202x | +87.75% |
| 2023-12-31 | $10.98 Million | $-18.09 Million | -1.647x | -99.72% |
| 2022-12-31 | $21.04 Million | $-17.35 Million | -0.825x | -121.63% |
| 2021-12-31 | $38.42 Million | $-14.30 Million | -0.372x | -222.43% |
| 2020-12-31 | $9.78 Million | $-1.13 Million | -0.115x | -253.20% |
| 2019-12-31 | $-4.49 Million | $-338.29K | 0.075x | +108.20% |
| 2018-12-31 | $-777.97K | $714.99K | -0.919x | -1147.82% |
| 2017-12-31 | $-1.44 Million | $-126.39K | 0.088x | +300.90% |
| 2016-12-31 | $-1.35 Million | $-29.57K | 0.022x | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more